Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer.

Clinical lung cancer - 1 Jan 2015

Lee Youngjoo, Lee Geon Kook, Hwang Jung-Ah, Yun Tak, Kim Heung Tae, Lee Jin Soo

Abstract excerpt

BACKGROUND: It has been reported that the presence of pretreatment EGFR T790M mutation may reduce the efficacy to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant lung cancer. However, clinicopathologic features related to the likelihood of T790M mutation before treatment remains unknown. PATIENTS AND METHODS: DNA from 124 pretreatment tissue samples from patients with advanced non-small-cell lung cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Likelihood Functions

Share to Mass Spectrometry

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Survival Analysis

Source

Identifiers

PMID: 25450875
DOI: 10.1016/j.cllc.2014.09.002

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer.PMID 25450875Read ↗

Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations.Semantic proximity Read ↗

Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Targeting the EGFR T790M mutation in non-small-cell lung cancer.Semantic proximity Read ↗

Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations.Semantic proximity Read ↗

Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.Semantic proximity Read ↗

Primary versus acquired epidermal growth factor receptor Thr790Met mutant non-small cell lung cancer: clinical features and prognoses.Semantic proximity Read ↗

Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer.Semantic proximity Read ↗

Screening for germline EGFR T790M mutations through lung cancer genotyping.Semantic proximity Read ↗

Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancerSemantic proximity Read ↗

Inherited Germline T790M Mutation and Somatic Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer PatientsSemantic proximity Read ↗

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.